免疫比濁試薬市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、用途別、地域別、競合別、2020～2030年

免疫比濁試薬の世界市場規模は2024年に54億米ドルとなり、予測期間では2030年までCAGR 6.10%で目覚ましい成長が見込まれています。

免疫比濁試薬は臨床診断、特に免疫学分野で極めて重要な役割を果たしています。この特殊なタイプの検査法は、溶液の濁りや濁度の程度を測定する比濁法の原理に依存しています。免疫比濁法では、この方法を用いて患者の血液サンプル中の特定のタンパク質や物質を定量的に測定します。プロセスは、患者の血清または血漿サンプルを、標的タンパク質または分析物に特異的な抗体を含む試薬に導入することから始まる。標的タンパク質がサンプル中に存在する場合、それは抗体と結合し、免疫複合体を形成します。これらの複合体は溶液を通過する光を散乱し、濁度が上昇します。この濁度の変化は標的分析物の濃度に正比例します。免疫比濁試薬は、免疫複合体の形成に必要な特異的抗体を含むため、このプロセスの重要な構成要素です。

これらの試薬は、高い特異性と感度を確保するために綿密に調合されており、標的タンパク質の正確な定量が可能です。さらに、サンプル中の他の物質からの干渉を最小限に抑えるように設計されているため、正確で信頼性の高い結果が得られます。イムノタービダイメトリーの主な利点の一つは、C反応性タンパク質（CRP）、免疫グロブリン、補体タンパク質のようなタンパク質を含む様々な分析対象物に幅広く適用できることです。このため、臨床検査室では、様々な疾患の状態を評価し、患者の健康状態をモニターするための汎用性の高いツールとなります。さらに、免疫比濁測定法は比較的迅速であり、タイムリーな臨床判断に重要な結果をタイムリーに提供します。さらに、免疫比濁法は自動化に適しており、患者サンプルのハイスループット分析が可能です。このことは臨床検査室の効率を高め、より短い時間枠で大量の検査を処理することを可能にします。免疫比濁法の自動化はまた、人為的ミスの可能性を減らし、結果の正確性と信頼性をさらに保証します。

市場促進要因

慢性疾患と感染症の有病率の上昇

主な市場課題

自動免疫化学製品の低い普及率

主な市場動向

自動化・高スループット診断システムの採用率上昇

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 免疫比濁試薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（共通免疫比濁試薬、ラテックス強化免疫比濁試薬）
  • 用途別（グリコヘモグロビン、レチノール結合タンパク質、C反応性タンパク質、抗連鎖球菌溶血素「O」、リウマチ因子、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の免疫比濁試薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の免疫比濁試薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の免疫比濁試薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の免疫比濁試薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの免疫比濁試薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の免疫比濁試薬市場：SWOT分析

第14章 競合情勢

• Danaher Corporation
• Abbott Laboratories Inc
• Siemens Healthineers AG
• F. Hoffmann-La Roche AG
• DIALAB GmbH
• Shanghai Kehua Bio-Engineering Co Ltd
• Randox Laboratories Ltd
• Beijing Leadman Biochemistry Co Ltd
• Fujifilm Corp
• Mindray Medical International Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Immunoturbidimetry Reagents Market was valued at USD 5.40 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.10% till 2030. Immunoturbidimetry reagents play a pivotal role in clinical diagnostics, particularly in the field of immunology. This specialized type of assay relies on the principle of turbidimetry, which measures the degree of turbidity or cloudiness in a solution. In immunoturbidimetry, this method is employed to quantitatively determine specific proteins or substances in a patient's blood sample. The process begins by introducing a patient's serum or plasma sample to a reagent containing antibodies specific to the target protein or analyte. If the target protein is present in the sample, it will bind with the antibodies, forming immune complexes. These complexes scatter light passing through the solution, resulting in an increase in turbidity. This change in turbidity is directly proportional to the concentration of the target analyte. Immunoturbidimetry reagents are crucial components of this process, as they contain the specific antibodies necessary for the formation of immune complexes.

These reagents are meticulously formulated to ensure high specificity and sensitivity, allowing for accurate quantification of the target protein. Moreover, they are designed to minimize interference from other substances in the sample, ensuring precise and reliable results. One of the key advantages of immunoturbidimetry is its wide applicability across a range of analytes, including proteins like C-reactive protein (CRP), immunoglobulins, and complement proteins. This makes it a versatile tool in clinical laboratories for assessing various disease states and monitoring patient health. Additionally, immunoturbidimetry assays are relatively rapid, providing timely results that are crucial for timely clinical decision-making. Furthermore, immunoturbidimetry is amenable to automation, allowing for high-throughput analysis of patient samples. This enhances the efficiency of clinical laboratories, enabling them to process a large volume of tests in a shorter timeframe. The automation of immunoturbidimetry also reduces the potential for human error, further ensuring the accuracy and reliability of results.

Key Market Drivers

Rising Prevalence of Chronic and Infectious Diseases

The increasing prevalence of chronic and infectious diseases is a significant driver propelling the expansion of the Global Immunoturbidimetry Reagents Market. As healthcare systems worldwide focus on early disease detection, monitoring, and effective management, the demand for high-precision diagnostic solutions such as immunoturbidimetry-based assays continue to rise. Chronic diseases, also known as non-communicable diseases (NCDs), have become the leading cause of mortality and morbidity worldwide. Conditions such as cardiovascular diseases (CVDs), diabetes, kidney diseases, autoimmune disorders, and cancer require continuous monitoring and early detection, creating a strong demand for accurate, reliable, and cost-effective diagnostic reagents like immunoturbidimetry reagents. According to a 2023 report by the World Heart Federation (WHF), global deaths from cardiovascular disease (CVD) surged from 12.1 million in 1990 to 20.5 million in 2021, reflecting a sharp increase in disease prevalence and associated risk factors. CVD remained the leading cause of death worldwide in 2021, with 80% of fatalities concentrated in low- and middle-income countries (LMICs). This trend underscores the urgent need for targeted healthcare investments, improved diagnostic capabilities, and scalable treatment solutions in these high-burden regions.

Biomarkers such as high-sensitivity C-reactive protein (hs-CRP), apolipoproteins (Apo A1 & Apo B), and fibrinogen are crucial for assessing cardiovascular risk and disease progression. Immunoturbidimetry reagents enable fast and cost-effective quantification of these biomarkers in routine clinical settings, increasing their adoption in diagnostic laboratories. By 2045, projections from the International Diabetes Federation (IDF) indicate that one in eight adults-approximately 783 million people-will be living with diabetes, marking a 46% increase from current levels. Notably, over 90% of cases will be type 2 diabetes, driven by a complex interplay of socioeconomic disparities, shifting demographics, environmental influences, and genetic predisposition. Regular monitoring of glycated hemoglobin (HbA1c) is essential for diabetes management. Immunoturbidimetry assays are widely used for HbA1c testing, offering a high-throughput, automated, and cost-effective solution.

The three most impactful pathogens were those responsible for tuberculosis (TB) at 65.1 million DALYs, malaria at 53.6 million, and HIV/AIDS at 52.1 million, highlighting their significant burden on global health. Notably, malaria parasites had the highest impact among children under five, contributing to 37.2 million DALYs, underscoring the urgent need for targeted interventions, improved access to treatment, and enhanced disease prevention strategies. The pandemic accelerated demand for immune response biomarkers such as ferritin, procalcitonin, D-dimer, and CRP, all of which can be analyzed using immunoturbidimetry reagents. Hospitals and diagnostic laboratories expanded their immunoturbidimetric testing capacities to monitor COVID-19-related complications, strengthening the market's growth trajectory. HIV/AIDS and hepatitis patients require frequent monitoring of immunoglobulins and inflammatory markers, both of which are efficiently measured using immunoturbidimetry-based assays. Tuberculosis remains a leading infectious disease, and the demand for serum protein analysis using immunoturbidimetry reagents has risen due to the need for accurate inflammation monitoring. Sepsis is a life-threatening condition requiring immediate detection of inflammatory biomarkers such as CRP, procalcitonin (PCT), and interleukin-6 (IL-6). Immunoturbidimetric tests provide fast and automated screening, enabling early intervention and reducing mortality rates.

Key Market Challenges

Low Adoption Rate of Automated Immunochemistry Products

The low adoption rate of automated immunochemistry products in developing economies presents a significant hindrance to the market's growth and advancement. While automated immunochemistry products offer numerous benefits, including enhanced efficiency, accuracy, and streamlined workflows, their uptake in these regions has been comparatively slow. One primary factor contributing to this challenge is the limited financial resources and budget constraints prevalent in many developing economies. The initial investment required for acquiring and implementing automated immunochemistry systems can be substantial, encompassing the cost of instrumentation, reagents, and the necessary infrastructure. In regions where healthcare budgets are constrained, prioritizing such investments can be a complex decision for healthcare facilities and institutions. Moreover, the maintenance and operational costs associated with automated immunochemistry systems may pose an ongoing financial burden for healthcare providers in these economies. This includes expenses related to instrument calibration, regular maintenance, and staff training. As a result, some healthcare facilities may be hesitant to make the transition from manual or semi-automated methods to fully automated immunochemistry platforms.

Key Market Trends

Rising Adoption of Automated and High-Throughput Diagnostic Systems

Automation is revolutionizing the clinical diagnostics industry, and immunoturbidimetry assays are increasingly being integrated into high-throughput laboratory analyzers. The demand for fast, accurate, and efficient testing solutions is leading to the widespread adoption of fully automated immunoassay platforms, which enhance diagnostic workflows and reduce human error.

Automated immunoturbidimetric systems can process a high volume of samples simultaneously, significantly reducing turnaround times and increasing laboratory productivity. Modern analyzers now incorporate artificial intelligence (AI) and machine learning (ML) algorithms to improve result accuracy, error detection, and predictive diagnostics. Automation ensures consistent and standardized immunoturbidimetric assay results, making it ideal for clinical laboratories, hospitals, and reference diagnostic centers. Hospitals and large diagnostic chains are investing in automated immunoturbidimetry analyzers to improve cost efficiency, reduce labor costs, and minimize reagent wastage. The integration of automated immunoturbidimetry systems with cloud-based data management and laboratory information systems (LIS) is expected to drive market growth by enabling seamless data sharing, remote monitoring, and enhanced laboratory efficiency.

Key Market Players

• Danaher Corporation
• Abbott Laboratories Inc
• Siemens Healthineers AG
• F. Hoffmann-La Roche AG
• DIALAB GmbH
• Shanghai Kehua Bio-Engineering Co Ltd
• Randox Laboratories Ltd
• Beijing Leadman Biochemistry Co Ltd
• Fujifilm Corp
• Mindray Medical International Ltd

Report Scope:

In this report, the Global Immunoturbidimetry Reagents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunoturbidimetry Reagents Market, By Type:

• Common Immune Turbidimetric Reagent
• Latex Enhanced Immune Turbidimetric Reagent

Immunoturbidimetry Reagents Market, By Application:

• Glycated hemoglobin
• Retinol Binding Protein
• C-Reactive Protein
• Anti-streptococcal hemolysin "O"
• Rheumatoid Factor
• Other

Immunoturbidimetry Reagents Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunoturbidimetry Reagents Market.

Available Customizations:

Global Immunoturbidimetry Reagents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Immunoturbidimetry Reagents Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Common Immune Turbidimetric Reagent, Latex Enhanced Immune Turbidimetric Reagent)
  • 5.2.2. By Application (Glycated hemoglobin, Retinol Binding Protein, C-Reactive Protein, Anti-streptococcal hemolysin "O", Rheumatoid Factor, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Immunoturbidimetry Reagents Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunoturbidimetry Reagents Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Immunoturbidimetry Reagents Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Immunoturbidimetry Reagents Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Immunoturbidimetry Reagents Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunoturbidimetry Reagents Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Immunoturbidimetry Reagents Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Italy Immunoturbidimetry Reagents Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. France Immunoturbidimetry Reagents Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Immunoturbidimetry Reagents Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Immunoturbidimetry Reagents Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Immunoturbidimetry Reagents Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Immunoturbidimetry Reagents Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Immunoturbidimetry Reagents Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Immunoturbidimetry Reagents Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Immunoturbidimetry Reagents Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. South America Immunoturbidimetry Reagents Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Immunoturbidimetry Reagents Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Immunoturbidimetry Reagents Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Immunoturbidimetry Reagents Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Immunoturbidimetry Reagents Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Immunoturbidimetry Reagents Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Immunoturbidimetry Reagents Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Immunoturbidimetry Reagents Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Immunoturbidimetry Reagents Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Danaher Corporation
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Abbott Laboratories Inc
• 14.3. Siemens Healthineers AG
• 14.4. F. Hoffmann-La Roche AG
• 14.5. DIALAB GmbH
• 14.6. Shanghai Kehua Bio-Engineering Co Ltd
• 14.7. Randox Laboratories Ltd
• 14.8. Beijing Leadman Biochemistry Co Ltd
• 14.9. Fujifilm Corp
• 14.10.Mindray Medical International Ltd

15. Strategic Recommendations

16. About Us & Disclaimer